The posters will present new data from the ongoing Phase 1b clinical trial of APN401, a candidate treatment from invIOs’s EPiC cell therapy platform targeting the master checkpoint inhibitor Cbl-b.
Dr Romana Gugenberger, CMSO, and Dr Alexander Dohnal, Head of R&D, will attend SITC 2022 and are available for meetings during the event.